没有发现贝达喹啉联合氟喹诺酮类、利奈唑胺和氯法齐明对广泛耐药结核病具有协同增效作用。
No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
机构信息
National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
出版信息
Diagn Microbiol Infect Dis. 2019 Aug;94(4):361-364. doi: 10.1016/j.diagmicrobio.2019.02.012. Epub 2019 Feb 19.
PURPOSE
We explored the potential synergistic effect of bedaquiline (BDQ) combined with moxifloxacin (MFX), gatifloxacin (GAT), clofazimine (CLO), and linezolid (LZD) for treatment of extensively drug-resistant tuberculosis (XDR-TB).
METHODS
Of 191 XDR-TB isolates, 20 exhibiting minimal inhibitory concentration (MIC) values ≥0.063 μg/mL for BDQ were selected to study potential synergistic, additive, or antagonistic drug effects using a checkerboard assay.
RESULTS
Antagonism occurred in 14 (70.0%), 0 (0.0%), 13 (65.0%), and 4 (20.0%) XDR-TB isolates for BDQ-MFX, BDQ-GAT, BDQ-LZD, and BDQ-CLO combinations, respectively.
CONCLUSION
Our in vitro data demonstrate no observed synergistic effects against XDR-TB for drug combinations that included BDQ in combination with MFX, GAT, LZD, or CLO.
目的
本研究旨在探索贝达喹啉（BDQ）联合莫西沙星（MFX）、加替沙星（GAT）、氯法齐明（CLO）和利奈唑胺（LZD）治疗广泛耐药结核病（XDR-TB）的潜在协同作用。
方法
在 191 株 XDR-TB 分离株中，选择 20 株对 BDQ 的最小抑菌浓度（MIC）值≥0.063μg/ml 的分离株，采用棋盘微量稀释法研究潜在的协同、相加或拮抗药物作用。
结果
BDQ-MFX、BDQ-GAT、BDQ-LZD 和 BDQ-CLO 组合分别在 14（70.0%）、0（0.0%）、13（65.0%）和 4（20.0%）株 XDR-TB 分离株中出现拮抗作用。
结论
本体外实验数据表明，BDQ 联合 MFX、GAT、LZD 或 CLO 治疗 XDR-TB 无协同作用。
Zotero 插件